Diabetes: How to reduce risk from a cardiovascular perspective?
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice
Prof. Grobbee discusses how to reduce CV risk in patients with T2DM, considering the effects of glucose control and additional effects observed in recent outcome trials of newer agents.
Video navigation menu
- Management of modifiable CV risk factors 01:07
- Lowering CV risk by glycemic control 02:37
- 21st century T2DM agents 07:38
- GLP-1 RA & DPP4-inhibitors: Mechanism of action / trials 08:28
- SGLT2-inhibition: mechanism of action / trial 09:20
This lecture by Prof. Grobbee was part of a CME accredited symposium: Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice, held during EuroPrevent in Ljubljana, Slovenia.
Professor Diederick Grobbee, MD - Professor of Clinical Epidemiology, University Medical Center Utrecht, The Netherlands
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Prof Grobbee received research grants, consulting fees and travel reimbursement from Astra-Zeneca, Bayer, Dutch Cancer Foundation, Dutch Medical Research Council (ZonMW), the European Union, the Netherlands Heart Foundation, MSD, NIH, NHLBI, Novo-Nordisk, Organon, Pfizer, Roche, Sanofi, Servier, StJude, Welcome Trust and Whyett.
Funding for this educational program was provided by an unrestricted educational grant from Novo Nordisk.